Understanding the Role of Mesenchymal Stromal Cells in Treating COVID-19 Acute Respiratory Distress Syndrome

O’Kane, Cecilia; Matthay, Michael A.

doi:10.1164/rccm.202209-1838ed

Cited by 5 publications

(3 citation statements)

References 19 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other than supportive care, treatments for severe COVID-19-related ARDS are currently limited to antivirals 18 , such as remdesivir 7,8 , or immune modulators, such as corticosteroids 9,10 , IL-6 antagonists 11,12 , or JAK inhibitors 13,14 ; all of which have shown limited or mixed evidence for reducing all-cause mortality in clinical trials. Other therapies currently undergoing evaluation include mesenchymal stromal cell (MSC) therapy, which offers an option for multi-target immune modulation 19 . Initial smaller trials of MSC therapy in COVID-19-related ARDS patients provided supportive evidence of efficacy in reducing all-cause mortality [20][21][22] .…”

Section: Discussionmentioning

confidence: 99%

“…Coronavirus disease 2019 (COVID- 19) has caused more than six million deaths globally, with most deaths being attributed to acute respiratory distress syndrome (ARDS) 1 , a condition caused by injury to the alveolar structure and surrounding microvasculature. Cases of severe COVID-19 have been associated with dysregulated host immune responses 2,3 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Phase 2, randomized, double-blind, placebo-controlled multi-center trial sub-study for the clinical effects of paridiprubart treatment in hospitalized critically ill patients with COVID-19 ARDS

Gordon,

Allum,

Brooks

et al. 2023

Preprint

View full text Add to dashboard Cite

BackgroundCoronavirus disease 2019 (COVID-19) mortality is predominantly due to acute respiratory distress syndrome (ARDS). There are currently limited treatment options for ARDS, a life-threatening condition with different etiologies, secondary to inflammation-induced lung injury. Paridiprubart is a monoclonal antibody that inhibits Toll-like Receptor 4 (TLR4), a key player in ARDS pathophysiology.MethodsThis was a prespecified sub-study of a randomized, double-blind, placebo-controlled, Phase 2 trial evaluating the efficacy and safety of paridiprubart in COVID-19 patients with ARDS receiving invasive mechanical ventilation and additional organ support. Efficacy outcomes were 28- and 60-day all-cause mortality, and improvement in COVID-19 severity and ventilation-free days at 28-days post-treatment.ResultsThirteen (13) and twenty (20) patients received paridiprubart and placebo, respectively. The groups were comparable for demographics and baseline parameters, except for higher kidney failure incidence and use of immune modulators and antivirals, and lower corticosteroids use in the paridiprubart group. Mortality at 28-days post-treatment was 7.7% (1/13) in the paridiprubart group versus 40.0% (8/20) for placebo (OR=0.125; 95% CI, 0.013-1.160; P=0.067; P[bootstrap]=0.011). 60-day mortality was 23.1% (3/13) in paridiprubart-treated patients and 45.0% (9/20) in placebo patients (OR=0.367; 95% CI, 0.077-1.749; P=0.208; P[bootstrap]=0.162). Mean survival time was 55.78 days for paridiprubart recipients compared to 41.44 days for placebo patients (HR=0.386; 95% CI, 0.077-1.436; P=0.156; P[bootstrap]=0.083). Although not statistically significant, results for other efficacy measures favored paridiprubart. Incidence of adverse events was similar in both groups.ConclusionsIn COVID-19 patients with ARDS requiring invasive ventilation and organ support, paridiprubart was efficacious in preventing mortality and improving clinical outcomes, with no safety concerns.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A Phase 2, randomized, double-blind, placebo-controlled multi-center trial sub-study for the clinical effects of paridiprubart treatment in hospitalized critically ill patients with COVID-19 ARDS

Gordon,

Allum,

Brooks

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…2 More than 1100.000 lives were lost because of the aforementioned pandemic in the Unites States, and intense efforts are devoted to oppose respiratory failure due to severe acute respiratory syndrome coronavirus 2. 3…”

mentioning

confidence: 99%